Fennec Pharmaceuticals resubmitted the company’s New Drug Application (NDA) to the U.S. Food and Drug Administration for the pediatric chemotherapy-induced hearing loss prevention drug Pedmark.
https://www.pharmalive.com/wp-content/uploads/2021/05/Fennec-Tries-Again-for-FDA-Approval-of-Chemotherapy-Induced-Hearing-Loss-Drug-BioSpace-5-28-21.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-05-28 12:11:102021-05-28 23:14:47Fennec Resubmits NDA for Chemotherapy-Induced Hearing Loss Drug